{"nct_id":"NCT07155174","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","status_verified_date":"2025-08","start_date":"2025-12-06","start_date_type":"ESTIMATED","primary_completion_date":"2031-09","primary_completion_date_type":"ESTIMATED","completion_date":"2031-09","completion_date_type":"ESTIMATED","phases":["PHASE2","PHASE3"],"tickers":["ABBV"]}